$145.31
+1.4%Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation
Base year metrics used for projections
Forecast period and terminal assumptions
Calculation flow from present value to intrinsic value per share
Operating Cash Flow - Maintenance CapEx = Owner Earnings
| Metric | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | Year 6 | Year 7 | Year 8 | Year 9 | Year 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $704.1M | $870.8M | $1.1B | $1.3B | $1.6B | $2.0B | $2.5B | $3.1B | $3.9B | $4.8B |
| Maintenance CapEx | -$47.4M | -$58.6M | -$72.5M | -$89.6M | -$110.9M | -$137.1M | -$169.6M | -$209.7M | -$259.4M | -$320.8M |
| Owner Earnings | $656.7M | $812.1M | $1.0B | $1.2B | $1.5B | $1.9B | $2.3B | $2.9B | $3.6B | $4.4B |
| Discount Factor | 0.926 | 0.857 | 0.794 | 0.735 | 0.681 | 0.630 | 0.583 | 0.540 | 0.500 | 0.463 |
| Present Value | $608.0M | $696.3M | $797.3M | $913.1M | $1.0B | $1.2B | $1.4B | $1.6B | $1.8B | $2.1B |
Continue your PODD research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.